SCHEMBL715285

SCHEMBL715285

CC(N)(C(=O)O)c1ccc(C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
SRD5A2 P31213 3/20 0.57
RARB P10826 1/20 0.56
RARG P13631 1/20 0.56
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
NR1H4 Q96RI1 3/20 0.49
EPHX2 P34913 2/20 0.49
CYP2D6 P10635 1/20 0.49
RXRA P19793 3/20 0.47
RXRB P28702 3/20 0.47
NR4A2 P43354 1/20 0.47
RXRG P48443 1/20 0.47
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP2C19 P33261 1/20 0.45
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410187 1.00 CYP1A2 (0.59) CYP1A2MEN1KMT2ASRD5A2RARB
SCHEMBL12648649 1.00 CYP1A2 (0.59) CYP1A2MEN1KMT2ASRD5A2RARB
SCHEMBL65824 0.83 SRD5A2 (0.61) CYP1A2MEN1KMT2ASRD5A2RARB
SCHEMBL29098742 0.83 SRD5A2 (0.61) CYP1A2MEN1KMT2ASRD5A2RARB
SCHEMBL10604183 0.82 NQO2 (0.51) CYP1A2MEN1KMT2ACYP2D6CYP2C19
Terephthalic Acid SCHEMBL31728631 0.82 TSHR (0.67) CYP1A2MEN1KMT2ASRD5A2RARB
SCHEMBL24208279 0.81 BLM (0.53) CYP1A2MEN1KMT2ATSHRCYP2D6
SCHEMBL16840188 0.81 SRD5A2 (0.59) CYP1A2MEN1KMT2ASRD5A2RARB
SCHEMBL11510852 0.81 CYP1A2 (0.54) CYP1A2MEN1KMT2ASRD5A2TSHR
SCHEMBL5427934 0.81 BLM (0.53) CYP1A2MEN1KMT2ATSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118041445-B Space laser communication terminal based on liquid crystal polarization grating and control method thereof 南京英田光学工程股份有限公司 2024-07-05 CN claimed
WO-2023196234-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-12 WO claimed
US-9499862-B2 Phospholinked dye analogs with an amino acid linker PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2016-11-22 US claimed
US-20150197794-A1 Phospholinked Dye Analogs with an Amino Acid Linker PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2015-07-16 US claimed
US-8993737-B2 Phospholinked dye analogs with an amino acid linker PACIFIC BIOSCIENCES, INC. (US) 2015-03-31 US claimed
US-20120052507-A1 PHOSPHOLINKED DYE ANALOGS WITH AN AMINO ACID LINKER PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2012-03-01 US claimed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 US disclosed
CN-115427458-A Transglutaminase mediated conjugation 塔拉克治疗公司 2022-12-02 CN disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
CN-113278634-B Novel vaccine for preventing and treating merkel cell carcinoma 艾棣维欣(苏州)生物制药有限公司 2022-06-28 CN disclosed
CN-111378599-B Degradation strain capable of simultaneously degrading two isomers of chiral herbicide 2, 4-dichlorprop and microbial inoculum produced by same 南京农业大学 2022-02-25 CN disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 US disclosed
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed
US-20070032474-A1 Use of a compound of formula 1 for making a pharmaceutical composition BIONDI RICARDO M 2007-02-08 US disclosed
US-20070032474-A1 Use of a compound of formula 1 for making a pharmaceutical composition BIONDI RICARDO M 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052507-A1 PHOSPHOLINKED DYE ANALOGS WITH AN AMINO ACID LINKER CHAMP1, MTAP, INCENP CYP1A2 4842/4885MEN1 1891/4885KMT2A 491/4885
US-20070032474-A1 Use of a compound of formula 1 for making a pharmaceutical composition CYP7A1, UGT1A1, CYP2F1 CYP1A2 30/4885MEN1 85/4885KMT2A 4178/4885
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CHLSN, PTMS, SRMS CYP1A2 4648/4885MEN1 2224/4885KMT2A 4241/4885
US-20150197794-A1 Phospholinked Dye Analogs with an Amino Acid Linker INCENP, CHAMP1, PNKP CYP1A2 4847/4885MEN1 3060/4885KMT2A 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.